(5-氨基-5,6,7,8-四氢萘-2-基)甲醇 | 784205-23-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: (5-氨基-5,6,7,8-四氢萘-2-基)甲醇
• 英文名称: (RS)-(5-amino-5,6,7,8-tetrahydronaphthalen-2-yl)methanol
• 英文别名: (5-amino-5,6,7,8-tetrahydronaphthalen-2-yl)methanol；(5(R)-Amino-5,6,7,8-tetrahydro-naphthalen-2-yl)-methanol
• CAS: 784205-23-8
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: LMNWQFGQPQCNCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5-氨基-5,6,7,8-四氢萘-2-基)甲醇 在 manganese(IV) oxide 、 silica-supported carbodiimide 、 1-羟基苯并三唑 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 52.0h， 生成 N-(6-formyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-3-(naphthalene-2-sulfonylamino)-3-phenyl-propionamide
  参考文献：
  名称：

  Identification of a Nonpeptidic and Conformationally Restricted Bradykinin B1 Receptor Antagonist with Anti-Inflammatory Activity

  摘要：

  We report the discovery of chroman 28, a potent and selective antagonist of human, nonhuman primate, rat, and rabbit bradykinin B1 receptors (0.4-17 nM). At 90 mg/kg s.c., 28 decreased plasma extravasation in two rodent models of inflammation. A novel method to calculate entropy is introduced and ascribed similar to 30% of the gained affinity between "flexible" 4 (K-i = 132 nM) and "rigid" 28 (K-i = 0.77 nM) to decreased conformational entropy.

  DOI：

  10.1021/jm061224g
• 作为产物：
  描述：

  5,6,7,8-四氢-5-氧代-2-萘羧酸甲酯 在 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 二苯基膦叠氮化物 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 0.08h， 生成 (5-氨基-5,6,7,8-四氢萘-2-基)甲醇
  参考文献：
  名称：

  Identification of a Nonpeptidic and Conformationally Restricted Bradykinin B1 Receptor Antagonist with Anti-Inflammatory Activity

  摘要：

  We report the discovery of chroman 28, a potent and selective antagonist of human, nonhuman primate, rat, and rabbit bradykinin B1 receptors (0.4-17 nM). At 90 mg/kg s.c., 28 decreased plasma extravasation in two rodent models of inflammation. A novel method to calculate entropy is introduced and ascribed similar to 30% of the gained affinity between "flexible" 4 (K-i = 132 nM) and "rigid" 28 (K-i = 0.77 nM) to decreased conformational entropy.

  DOI：

  10.1021/jm061224g

文献信息

• [EN] SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS<br/>[FR] TÉTRAHYDROAZOLOPYRAZINES SULFONYLÉES ET LEUR UTILISATION EN TANT QUE PRODUITS MÉDICAMENTEUX
  申请人：GRUENENTHAL GMBH

  公开号：WO2010099938A1

  公开（公告）日：2010-09-10

  The present invention relates to sulfonylated tetrahydroazolopyrazines, methods for the preparation thereof, medicinal products containing these compounds and the use of substituted indole compounds for the preparation of medicinal products (Formula I).

  本发明涉及磺酰化四氢咯啉吡嗪，其制备方法，含有这些化合物的药物产品以及用于制备药物产品的取代吲哚化合物的使用（式I）。
• [EN] BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] COMPOSES BICYCLIQUES PRESENTANT UNE AFFINITE POUR LES RECEPTEURS DE LA BRADYKININE ET COMPOSITIONS PHARMACEUTIQUES EN CONTENANT
  申请人：AMGEN INC

  公开号：WO2004092116A1

  公开（公告）日：2004-10-28

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疼痛和炎症介导的疾病等方面有效。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，以及用于预防和治疗涉及疼痛、炎症等疾病和其他疾病或病况的药物组合物和方法。该发明还涉及制备这类化合物的方法，以及在这类方法中有用的中间体。
• Piperazine derivatives and methods of use
  申请人：Chen J. Jian

  公开号：US20050014749A1

  公开（公告）日：2005-01-20

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疼痛和炎症介导的疾病等方面有效。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，以及用于预防和治疗涉及疼痛、炎症等疾病或其他疾病或病况的药物组合物和方法。该发明还涉及制备这类化合物的方法，以及在这类方法中有用的中间体。
• [EN] SUBSTITUTED SULFONAMIDOPROPIONAMIDES AND METHODS OF USE<br/>[FR] SULFONAMIDOPROPIONAMIDES SUBSTITUES ET PROCEDES D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2006036664A1

  公开（公告）日：2006-04-06

  This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating inflammation-related disorders, including pain.

  这项发明属于药物代理领域，具体涉及化合物、组合物、用途和治疗与炎症相关的疾病，包括疼痛的方法。
• 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use
  申请人：Askew C. Benny

  公开号：US20060025400A1

  公开（公告）日：2006-02-02

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疼痛和疾病，如炎症介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，药物组合物以及用于预防和治疗涉及疼痛、炎症等疾病和其他不适或情况的方法。该发明还涉及制备此类化合物的方法，以及在此类过程中有用的中间体。